King Keeps Medicaid Business, Gives Up $124 Mil. Under Rebate Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
The "relator" could object to the settlements, which might prevent consummation of agreements with states and the federal government.
You may also be interested in...
King Expects Settlements With SEC and OIG Will Not Exceed $130 Mil.
King anticipates that the cost of settling Medicaid underpayment investigations will not exceed the $130 mil. already set aside
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.